Kissling Sébastien, Legallais Cécile, Pruijm Menno, Teta Daniel, Vogt Bruno, Burnier Michel, Rondeau Eric, Ridel Christophe
Service d'Urgences néphrologiques et Transplantation rénale (UNTR), Hôpital Tenon, Paris, 75020, France.
Biomécanique et Bioingénierie, Université de Technologie de Compiègne (UTC), UMR CNRS 7338, Compiègne, 60203, France.
BMC Nephrol. 2017 Mar 1;18(1):81. doi: 10.1186/s12882-017-0494-9.
Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for clinical practice.
The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized prescriptions of citrate.
Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid-base disturbances.
We propose a new protocol, which enables for the first time to individualize the prescription of regional citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects against both the risk of coagulation of the membrane and the exposure to an excess of citrate.
区域枸橼酸盐抗凝(RCA)被应用于各种体外净化技术,以克服全身抗凝可能导致的出血风险。然而,迄今为止尚未针对治疗性血浆置换(TPE)提出个体化治疗方案。本研究的目的是评估所需血枸橼酸盐浓度的决定因素,并制定一种适用于临床实践的个体化RCA方案。
研究人群包括14例患者,共进行了47次TPE治疗。枸橼酸盐在血浆滤器前输注。在标准化时间间隔测量血浆滤器后和全身血浆离子钙浓度。提出了一种补钙算法。在探索阶段,枸橼酸盐以固定的起始速率输注,并根据获得的血浆滤器后离子钙水平进行调整。此后,使用数学方法开发了一种用于枸橼酸盐个体化处方的算法。
血细胞比容和血浆离子钙的治疗前值是枸橼酸盐输注所需速率的主要决定因素。这些因素可整合到一个最终方程中,以实现处方个体化。滤器前离子钙浓度在0.24至0.33 mmol/l之间可防止体外循环凝血。8.5%的治疗中出现了明显的低钙血症。没有明显的酸碱紊乱。
我们提出了一种新方案,首次能够有效地在TPE期间对区域枸橼酸盐抗凝处方进行个体化。立即获得的区域抗凝可防止膜凝血风险和枸橼酸盐过量暴露。